Sionna Therapeutics, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- Sionna Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 5.96, a 7.31% increase year-over-year.
- Sionna Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 6.58, a 25.11% decline year-over-year.
- Sionna Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 5.07, a 36.41% increase year-over-year.
- Sionna Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 5.26.
- Sionna Therapeutics, Inc. quick ratio for fiscal 2025 was 5.07, a 36.41% increase from fiscal 2024.
- Sionna Therapeutics, Inc. quick ratio for fiscal 2024 was 3.72.
- Available history
- 2024-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |